Research progress in the diagnosis and treatment of immune checkpoint inhibitors related myocarditis
LIAO Chunyao1 WU Lidong1▲ LIAO Mengyan2
1.Department of Emergency,the Second Affiliated Hospital of Nanchang University,Jiangxi Province,Nanchang 330006,China;
2.Department of Clinical Medicine,Fuzhou Medical College of Nanchang University,Jiangxi Province,Fuzhou 344099,China
Abstract：With the widespread development of oncology and immunology in clinical practice,its application in the treatment of malignant tumor patients has become the most advanced treatment method in the field of anti-tumor therapy.As a new type of anti-tumor drug,immune checkpoint inhibitors(ICIs)are an important method for implementing immunotherapy in cancer patients and have been widely used in the treatment of malignant tumor patients.The use of ICIs is particularly important for improving the prognosis of advanced malignant tumor patients,bringing breakthrough progress to the treatment of malignant tumor patients,and can greatly prolong their survival time and improve their quality of life.However,the treatment of ICIs inevitably brings about immune related adverse reactions,among which ICIs related myocarditis has a higher risk of occurrence.Currently,there is no clear definition of the pathogenesis and etiology of ICIs related myocarditis in clinical practice,which may be closely related to factors such as T cell activation,immune testing,and the production of autoantibodies.If patients are not diagnosed and treated in a timely manner during this process,it can pose a serious threat to their life safety.Therefore,this article reviews the definition and pathogenesis of ICIs related myocarditis,clinical diagnosis of ICIs related myocarditis,and clinical treatment of ICIs related myocarditis,providing effective reference for clinical treatment of ICIs related myocarditis.
京公网安备 11010502046607号